- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc (GILD34)
Gilead Sciences Inc stock price live, this page displays BVMF GILD34 stock exchange data. View the GILD34 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gilead Sciences Inc real time stock price chart below.
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 307.61.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD34.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the B3 stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD34 quote. (ISIN: BRGILDBDR000)
What Is the Gilead Sciences Inc Stock Price Today?
The Gilead Sciences Inc stock price today is 307.61.
What Is the Stock Symbol for Gilead Sciences Inc?
The stock symbol for Gilead Sciences Inc is ""GILD34.""
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the B3 stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead Sciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GILD34 quote. (ISIN: BRGILDBDR000)
307.61
+3.19(+1.05%)
Closed·
Fair Value
An estimate of a Gilead Sciences DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
307.61
307.61
52 wk Range
218.56
345.65
GILD34 Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
GILD34 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Gilead Sciences DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
307.61307.61
52 wk Range
218.56345.65
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.88%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(1.88%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GILD34 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Gilead Sciences DRC's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Gilead Sciences Inc Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Compare GILD34 to Peers and Sector
Metrics to compare | GILD34 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILD34PeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.2x | −2.0x | −0.5x | |
PEG Ratio | 0.04 | −0.02 | 0.00 | |
Price/Book | 7.1x | 1.0x | 2.6x | |
Price / LTM Sales | 4.9x | 16.2x | 3.3x | |
Upside (Analyst Target) | - | 82.9% | 38.9% | |
Fair Value Upside | Unlock | 16.0% | 5.4% | Unlock |
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
1.56 / --
Revenue / Forecast
7.08B / --
FAQ
What Stock Exchange Does Gilead Sciences DRC Trade On?
Gilead Sciences DRC is listed and trades on the B3 Stock Exchange stock exchange.
What Is the Stock Symbol for Gilead Sciences DRC?
The stock symbol for Gilead Sciences DRC is "GILD34."
What Is the Gilead Sciences DRC Market Cap?
As of today, Gilead Sciences DRC market cap is 761.20B.
What Is Gilead Sciences DRC's Earnings Per Share (TTM)?
The Gilead Sciences DRC EPS (TTM) is 5.06.
From a Technical Analysis Perspective, Is GILD34 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Gilead Sciences DRC Stock Split?
Gilead Sciences DRC has split 0 times.
How Many Employees Does Gilead Sciences DRC Have?
Gilead Sciences DRC has 17600 employees.
What is the current trading status of Gilead Sciences DRC (GILD34)?
As of 30 Aug 2025, Gilead Sciences DRC (GILD34) is trading at a price of 307.61, with a previous close of 304.42. The stock has fluctuated within a day range of 307.61 to 307.61, while its 52-week range spans from 218.56 to 345.65.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.